XML 32 R24.htm IDEA: XBRL DOCUMENT
v3.23.4

FINANCIAL INSTRUMENTS | 6 Months Ended
--- | ---
Jun. 30, 2023
Notes and other explanatory information [abstract] |
FINANCIAL INSTRUMENTS |
| 16. | FINANCIAL INSTRUMENTS
(a) Financial assets Set out below is an overview of financial assets, other than cash and short-term deposits, held by the Group as of December 31, 2022 and June 30, 2023:
Schedule of financial assets |  |  |  |  |  |  |  |  |
|  | December 31, |  |  | June 30, |
|  | 2022 |  |  | 2023 |  |  | 2023 |
|  | CNY |  |  | CNY |  |  | US$ |
|  | (Audited) |  |  | (Unaudited) |  |  | (Unaudited) |
Debt instruments at amortized cost: |  |  |  |  |  |  |  |  |  |  |  |
Trade receivables: current |  |  | 46,760 |  |  |  | 56,274 |  |  |  | 7,758 |
Trade receivables: non-current |  |  | 10,520 |  |  |  | 4,714 |  |  |  | 650 |
Financial assets included in other receivables |  |  | 82,406 |  |  |  | 78,943 |  |  |  | 10,883 |
Financial assets at fair value through other comprehensive income: |  |  |  |  |  |  |  |  |  |  |  |
Bills receivable |  |  | 8,500 |  |  |  | 9,200 |  |  |  | 1,268 |
Total |  |  | 148,186 |  |  |  | 149,131 |  |  |  | 20,559 |
Total Current |  |  | 137,666 |  |  |  | 144,417 |  |  |  | 19,909 |
Total Non-current |  |  | 10,520 |  |  |  | 4,714 |  |  |  | 650 |
(b) Financial liabilities Set out below, is an overview of financial liabilities of the Group as of December 31, 2022 and June 30, 2023:
Schedule of financial liabilities |  |  |  |  |  |  |  |  |
|  | December 31, |  |  | June 30, |  |  | June 30 |
|  | 2022 |  |  | 2023 |  |  | 2023 |
|  |  | CNY |  |  |  | CNY |  |  |  | US$ |
|  |  | (Audited) |  |  |  | (Unaudited) |  |  |  | (Unaudited) |
Derivatives not designated as hedging instruments： |  |  |  |  |  |  |  |  |  |  |  |
Derivative financial liabilities (i) |  |  | 824 |  |  |  | 958 |  |  |  | 132 |
Financial liabilities at amortized cost: |  |  |  |  |  |  |  |  |  |  |  |
Trade payables |  |  | 20,326 |  |  |  | 21,529 |  |  |  | 2,968 |
Financial liabilities in other payables and accruals |  |  | 6,749 |  |  |  | 83,809 |  |  |  | 11,555 |
Lease liabilities |  |  | 2,915 |  |  |  | 2,382 |  |  |  | 330 |
Due to related companies |  |  | 3,408 |  |  |  | 6,117 |  |  |  | 843 |
Due to the Shareholder |  |  | 7,153 |  |  |  | 184,054 |  |  |  | 25,375 |
Interest-bearing loans and borrowings |  |  | 74,000 |  |  |  | 72,500 |  |  |  | 9,996 |
Total |  |  | 115,375 |  |  |  | 371,349 |  |  |  | 51,199 |
Total current |  |  | 42,777 |  |  |  | 301,276 |  |  |  | 41,538 |
Total non-current |  |  | 72,598 |  |  |  | 70,073 |  |  |  | 9,661 |
| (i) | On January 20, 2021, the Company entered into a securities purchase agreement with certain institutional investors, pursuant to which the Company issued and sold on January 22, 2021, (i) in a registered direct offering, an aggregate of 3,960,000 of its common shares at a price of US$1.85 per share, and (ii) in a concurrent private placement, warrants initially exercisable for an aggregate of 1,584,000* of the Company's common shares with an initial exercise price of US$2.35* per share.
The Company recognized the warrants issued to the investors as derivative financial liabilities (not designated as hedging instruments) with a fair value of CNY9,246 (US$1,427)** on the issue date as the investors have the right to exercise their warrants on a cashless basis. Per IAS 32, a contract settled by a single net payment (generally referred to as net cash-settled or net equity-settled as the case may be) is a financial liability and not an equity instrument. The fair value gain of CNY559 and fair value loss of CNY86 (US$12) (Note 6) were recognized according to fair value changes for the six months ended June 30, 2022 and 2023, respectively. * On July 14, 2022, the exercise price for the Company’s outstanding warrants was reduced to the amount, 0.623$* per share, equal to the new issuance price of options granted under the China Natural Resources, Inc. 2014 Equity Compensation Plan pursuant to the terms of the warrants. On April 3, 2023, the number of shares under these warrants were adjusted to 316,800 and the exercise prices of these warrants were adjusted to US$3.115 per share due to the Company effected a share combination in which all of the Company's issued and outstanding ordinary shares were combined on a 5-to-1 basis. ** As the changes in equity from this private placement transaction are denominated in US$, the amount in US$ is the actual transaction amount and the corresponding amount in CNY was translated from US$ at the applicable exchange rate of the transaction date, January 22, 2021. (c) Fair value Set out below is a comparison, by class, of the carrying amounts and fair values of the Group’s financial instruments, other than those with carrying amounts that are reasonable approximations of fair values:
Schedule of group’s financial instruments carrying amount |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | December 31, |  |  | June 30, |
|  | 2022 |  |  | 2023 |  |  | 2023 |
|  | CNY |  |  | CNY |  |  | US$ |
|  | (Audited) |  |  | (Unaudited) |  |  | (Unaudited) |
|  | Carrying amount |  |  | Fair value |  |  | Carrying amount |  |  | Fair value |  |  | Carrying amount |  |  | Fair value |
Financial liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest-bearing loans and borrowings |  |  | 74,000 |  |  |  | 77,636 |  |  |  | 72,500 |  |  |  | 76,396 |  |  |  | 9,996 |  |  |  | 10,532 |
Total |  |  | 74,000 |  |  |  | 77,636 |  |  |  | 72,500 |  |  |  | 76,396 |  |  |  | 9,996 |  |  |  | 10,532 |
The following table provides the fair value measurement hierarchy of the Group’s financial assets and financial liabilities as of December 31, 2022 and June 30, 2023:
Schedule of fair value measurement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
As of December 31, 2022 |  | Fair value measurement using |
|  | Quoted prices in active markets (Level 1) |  |  | Significant observable inputs (Level 2) |  |  | Significant unobservable inputs (Level 3) |  |  | Total |
|  | CNY |  |  | CNY |  |  | CNY |  |  | CNY |
Recurring fair value measurement: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Financial assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Bills receivable |  |  | — |  |  |  | 8,500 |  |  |  | — |  |  |  | 8,500 |
Financial liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Derivative financial liabilities |  |  | — |  |  |  | 824 |  |  |  | — |  |  |  | 824 |
As of June 30, 2023 (Unaudited) |  | Fair value measurement using |
|  | Quoted prices in active markets (Level 1) |  |  | Significant observable inputs (Level 2) |  |  | Significant unobservable inputs (Level 3) |  |  | Total |
|  | CNY |  |  | CNY |  |  | CNY |  |  | CNY |
Recurring fair value measurement: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Financial assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Bills receivables |  |  | — |  |  |  | 9,200 |  |  |  | — |  |  |  | 9,200 |
Financial liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Derivative financial liabilities |  |  | — |  |  |  | 958 |  |  |  | — |  |  |  | 958 |
As of June 30, 2023 (Unaudited) |  | Fair value measurement using |
|  | Quoted prices in active markets (Level 1) |  |  | Significant observable inputs (Level 2) |  |  | Significant unobservable inputs (Level 3) |  |  | Total |
|  | US$ |  |  | US$ |  |  | US$ |  |  | US$ |
Recurring fair value measurement: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Financial assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Bills receivables |  |  | — |  |  |  | 1,268 |  |  |  | — |  |  |  | 1,268 |
Financial liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Derivative financial liabilities |  |  | — |  |  |  | 132 |  |  |  | — |  |  |  | 132 |
Level 2: Bills receivable The fair value valuation of bills receivable is based on directly or indirectly observable inputs (such as recent bill discount rates) through valuation techniques. The fair value of the bills receivable approximate their book value due to the short-term maturity. Derivative financial liabilities The fair value of financial instruments that are not traded in an active market is determined by using valuation techniques. These valuation techniques maximize the use of relevant observable inputs and minimize the use of unobservable inputs. If all significant inputs required to fair value an instrument are observable, the instrument is included in Level 2. There is no established public trading market for the warrants issued to investors on January 22, 2021. As of June 30, 2023, the Group measured the fair value of those warrants on a recurring basis using a binomial lattice pricing model with significant inputs including the underlying spot price of the Company’s ordinary shares, exercise price, time to expiration, risk-free rate, and equity volatility, etc., which are all relevant observable inputs.

X
- Definition The entire disclosure for financial instruments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 7 -IssueDate 2023-01-01 -Section Scope -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI -URIDate 2023-03-23 + Details
Name: | ifrs-full_DisclosureOfFinancialInstrumentsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_NotesAndOtherExplanatoryInformationAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration